Moderna's valuation gains sustain through 2026 due to biodefense positioning

Moderna will leverage its mRNA platform to develop a hantavirus vaccine candidate within 12 months, securing pre-orders or advanced purchase agreements from governments. This will drive a sustained 15%+ stock price increase by Q4 2026.

Implied probability (Yes)

70%